Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry

As of the February 12 closing, Dyne Therapeutics (NASDAQ:DYN) held a powerfully bullish statement view. Of the 9 analysts covering the stock, 7 assigned Buy ratings and 2 issued Hold ratings. With nary Sell rating, the banal has a projected median 1-year terms people of $39.33, implying astir 146% upside.

Billion Photos/Shutterstock.com

On January 20, Dyne Therapeutics (DYN) reported that Japan’s Ministry of Health, Labour and Welfare granted Orphan Drug designation to the company’s experimental cause zeleciment-basivarsen to dainty myotonic muscular dystrophy benignant 1, DM1. The company’s Chief Medical Officer Doug Kerr, M.D., Ph.D., stated:

”By targeting the underlying biology of DM1, z-basivarsen has shown aboriginal and sustained improvements successful myotonia, musculus spot and function, with a favorable information profile. This designation successful Japan, alongside those already granted successful the U.S. and Europe, emphasizes the urgent request for caller therapies and highlights the imaginable of z-basivarsen to present meaningful functional betterment for radical surviving with DM1.”

Dyne Therapeutics (NASDAQ:DYN) is simply a biotechnology institution that formulates life-transforming targeted therapeutics for individuals with genetically driven neuromuscular diseases. Dyne Therapeutics (NASDAQ:DYN) uses its FORCE level to place the basal origin of a information and presently has a beardown pipeline of objective and preclinical programs.

While we admit the imaginable of DYN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.